2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Scott M Grundy, Neil J Stone, Alison L Bailey, Craig Beam, Kim K Birtcher, Roger S Blumenthal, Lynne T Braun, Sarah de Ferranti, Joseph Faiella-Tommasino, Daniel E Forman, Ronald Goldberg, Paul A Heidenreich, Mark A Hlatky, Daniel W Jones, Donald Lloyd-Jones, Nuria Lopez-Pajares, Chiadi E Ndumele, Carl E Orringer, Carmen A Peralta, Joseph J Saseen, Sidney C Smith Jr, Laurence Sperling, Salim S Virani, Joseph Yeboah, Scott M Grundy, Neil J Stone, Alison L Bailey, Craig Beam, Kim K Birtcher, Roger S Blumenthal, Lynne T Braun, Sarah de Ferranti, Joseph Faiella-Tommasino, Daniel E Forman, Ronald Goldberg, Paul A Heidenreich, Mark A Hlatky, Daniel W Jones, Donald Lloyd-Jones, Nuria Lopez-Pajares, Chiadi E Ndumele, Carl E Orringer, Carmen A Peralta, Joseph J Saseen, Sidney C Smith Jr, Laurence Sperling, Salim S Virani, Joseph Yeboah

No abstract available

Keywords: AHA Scientific Statements; Guidelines; biomarkers, coronary artery calcium score; cardiovascular disease; cholesterol, LDL-cholesterol; diabetes mellitus; drug therapy; ezetimibe; hydroxymethylglutaryl-CoA reductase inhibitors/statins; hypercholesterolemia; lipids; patient compliance; pharmacological; primary prevention; proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9) inhibitors; risk assessment; risk reduction discussion; risk treatment discussion, secondary prevention.